Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Agios Pharmaceuticals Inc’s stock clocked out at $34.34, down -0.29% from its previous closing price of $34.44. In other words, the price has decreased by -$0.29 from its previous closing price. On the day, 0.84 million shares were traded.
Ratios:
To gain a deeper understanding of AGIO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.56 and its Current Ratio is at 11.90. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on February 24, 2025, initiated with a Buy rating and assigned the stock a target price of $58.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 05 ’25 when Washburn Theodore James Jr. sold 2,272 shares for $34.39 per share. The transaction valued at 78,134 led to the insider holds 5,437 shares of the business.
Milanova Tsveta sold 2,804 shares of AGIO for $90,233 on Jan 06 ’25. The Chief Commercial Officer now owns 18,906 shares after completing the transaction at $32.18 per share. On Jan 03 ’25, another insider, Milanova Tsveta, who serves as the Officer of the company, bought 2,804 shares for $31.84 each.
Valuation Measures:
As of this moment, Agios’s Price-to-Earnings (P/E) ratio for their current fiscal year is 3.01. For the stock, the TTM Price-to-Sale (P/S) ratio is 53.91 while its Price-to-Book (P/B) ratio in mrq is 1.27.
Stock Price History:
Over the past 52 weeks, AGIO has reached a high of $62.58, while it has fallen to a 52-week low of $27.14. The 50-Day Moving Average of the stock is -0.42%, while the 200-Day Moving Average is calculated to be -19.98%.
Shares Statistics:
A total of 57.16M shares are outstanding, with a floating share count of 55.21M. Insiders hold about 3.64% of the company’s shares, while institutions hold 106.81% stake in the company.
Earnings Estimates
A comprehensive evaluation of Agios Pharmaceuticals Inc (AGIO) is underway, with the input of 3.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$1.85, with high estimates of -$1.7 and low estimates of -$1.97.
Analysts are recommending an EPS of between -$6.49 and -$7.81 for the fiscal current year, implying an average EPS of -$7.19. EPS for the following year is -$5.8, with 4.0 analysts recommending between -$4.9 and -$6.45.
Revenue Estimates
In the current quarter, 7 analysts expect revenue to total $10.19M. It ranges from a high estimate of $12.21M to a low estimate of $9.04M. As of the current estimate, Agios Pharmaceuticals Inc’s year-ago sales were $8.19MFor the next quarter, 7 analysts are estimating revenue of $10.86M. There is a high estimate of $13.5M for the next quarter, whereas the lowest estimate is $9.8M.
A total of 10 analysts have provided revenue estimates for AGIO’s current fiscal year. The highest revenue estimate was $78.31M, while the lowest revenue estimate was $42M, resulting in an average revenue estimate of $53.96M. In the same quarter a year ago, actual revenue was $36.5MBased on 10 analysts’ estimates, the company’s revenue will be $170.63M in the next fiscal year. The high estimate is $217.25M and the low estimate is $111M.
